Cargando…

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

BACKGROUND & AIMS: Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. METHODS: We profiled 2,083 serum miRNAs in a discovery cohort (183 cases w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Katherine, Leary, Peter J., Govaere, Olivier, Barter, Matthew J., Charlton, Sarah H., Cockell, Simon J., Tiniakos, Dina, Zatorska, Michalina, Bedossa, Pierre, Brosnan, M. Julia, Cobbold, Jeremy F., Ekstedt, Mattias, Aithal, Guruprasad P., Clément, Karine, Schattenberg, Jörn M., Boursier, Jerome, Ratziu, Vlad, Bugianesi, Elisabetta, Anstee, Quentin M., Daly, Ann K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762473/ https://www.ncbi.nlm.nih.gov/pubmed/35072021 http://dx.doi.org/10.1016/j.jhepr.2021.100409

Ejemplares similares

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
por: Govaere, Olivier, et al.
Publicado: (2023)

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
por: Sen, Partho, et al.
Publicado: (2022)

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
por: Boyle, Marie, et al.
Publicado: (2019)

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
por: McGlinchey, Aidan J., et al.
Publicado: (2022)

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
por: McPherson, Stuart, et al.
Publicado: (2017)

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
por: Liu, Yang-Lin, et al.
Publicado: (2014)

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Mak, Anne Linde, et al.
Publicado: (2021)

Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study
por: O'Hara, Jamie, et al.
Publicado: (2020)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

Assessing the disease burden of non-alcoholic fatty liver disease in the real world – big data and big numbers
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

The $^{191,193}$Hg and $^{191,193}$Au positon decays
por: Vieu, C, et al.
Publicado: (1976)

European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?
por: Lazarus, Jeffrey V., et al.
Publicado: (2021)

FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
por: Vali, Yasaman, et al.
Publicado: (2021)

Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis
por: Lee, Jenny, et al.
Publicado: (2020)

Configurations of superdeformed bands in $^{193}$Pb
por: Ducroux, L, et al.
Publicado: (1996)

The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326
por: Ford, Brian E., et al.
Publicado: (2023)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis
por: Newsome, Philip N., et al.
Publicado: (2023)

Magnetic properties of superdeformed $^{193}$Hg and $^{195}$Ti nuclei
por: Azaiez, F, et al.
Publicado: (1994)

LIN92#19.3
Publicado: (1993)

AB193. Rectourethral fistula
por: Jiang, Hai
Publicado: (2016)

Health Tract, No. 193: Bread
Publicado: (1865)

Health Tract, No. 193: Bread
Publicado: (1864)

193. Comparison of Survival for MSSA and MRSA Endocarditis
por: Kanyo, Emese, et al.
Publicado: (2019)

193. Duration of Antimicrobial Therapy: The Impact of Defaults
por: Wrenn, Rebekah, et al.
Publicado: (2018)

Dipole bands and multi-particle excitations in $^{193}Pb$
por: Ducroux, L, et al.
Publicado: (1996)

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
por: Newsome, Philip N, et al.
Publicado: (2020)

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
por: Kozumi, Kazuhiro, et al.
Publicado: (2021)

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
por: Vali, Yasaman, et al.
Publicado: (2022)

Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy
por: Thiagarajan, Prarthana, et al.
Publicado: (2021)

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis
por: Erhardtsen, Elisabeth, et al.
Publicado: (2021)

High spin states in $^{189,191,193}$Au
por: Gono, Y, et al.
Publicado: (1976)

Overall view of AA in Bld. 193
Publicado: (1980)

Overall view of AA (Bld 193)
Publicado: (1980)

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial
por: Wai-Sun Wong, Vincent, et al.
Publicado: (2023)

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19
por: Deckmyn, Olivier, et al.
Publicado: (2022)

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
por: Mózes, Ferenc Emil, et al.
Publicado: (2022)

Histological, epidemiological and anatomical analysis of 193 bone tumours of the scapula
por: Priemel, Matthias H., et al.
Publicado: (2019)

Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis
por: Schattenberg, Jörn M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vidfmo8cov7oetto3mg6ka4du7